Charles River Laboratories International, Inc. (NYSE:CRL) Stock Has Consensus Target Price of $290.00 According to Analysts

Charles River Laboratories International, Inc. (NYSE:CRL) has earned a consensus rating of “Moderate Buy” from the seventeen research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, thirteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $300.11.

Several equities research analysts have recently issued reports on the stock. Robert W. Baird raised their price target on shares of Charles River Laboratories International from $291.00 to $334.00 and gave the stock an “outperform” rating in a research note on Friday, September 25th. Mizuho raised their target price on Charles River Laboratories International from $264.00 to $295.00 and gave the stock a “neutral” rating in a research report on Friday, September 25th. BNP Paribas Exane set a $250.00 price objective on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Jefferies Financial Group boosted their target price on shares of Charles River Laboratories International from $305.00 to $340.00 and gave the company a “buy” rating in a report on Monday. Finally, Morgan Stanley increased their target price on Charles River Laboratories International from $260.00 to $300.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th.

Charles River Laboratories International Trading Up 1.2%

Shares of Charles River Laboratories International stock opened at $290.32 on Wednesday. The firm has a market cap of $13.86 billion, a PE ratio of -59.86, a P/E/G ratio of 2.67 and a beta of 1.40. Charles River Laboratories International has a 1 year low of $146.20 and a 1 year high of $303.30. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The stock has a fifty day moving average price of $277.46 and a 200-day moving average price of $217.53.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. During the same period in the previous year, the firm earned $3.12 EPS. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Equities research analysts anticipate that Charles River Laboratories International will post 11.42 EPS for the current year.

Insider Activity

In other Charles River Laboratories International news, Director Nancy C. Andrews sold 573 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total value of $163,442.52. Following the completion of the sale, the director owned 1,438 shares of the company’s stock, valued at $410,175.12. This represents a 28.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Victoria L. Creamer sold 4,179 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the sale, the executive vice president owned 30,051 shares in the company, valued at approximately $7,788,017.16. The trade was a 12.21% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 90,990 shares of company stock worth $25,731,388. Corporate insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP grew its position in shares of Charles River Laboratories International by 14.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock valued at $285,001,000 after acquiring an additional 210,260 shares during the period. Geode Capital Management LLC boosted its holdings in Charles River Laboratories International by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company’s stock valued at $254,186,000 after purchasing an additional 9,756 shares during the last quarter. Bank of America Corp DE increased its stake in Charles River Laboratories International by 5.0% during the first quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock worth $195,792,000 after acquiring an additional 54,500 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Charles River Laboratories International by 8.7% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 836,240 shares of the medical research company’s stock worth $166,813,000 after purchasing an additional 66,803 shares in the last quarter. Finally, Amundi grew its stake in shares of Charles River Laboratories International by 175.2% in the first quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after buying an additional 492,301 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products.

Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications.

Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia.